Childhood acute lymphoblastic leukemia

Indexed in Crossref

27 abstracts matching childhood acute lymphoblastic leukemia from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:45 UTC. This is a keyword search, not the complete abstract book.

• E18528
  Response to venetoclax-containing regimens in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).

  Miles Thomas, Apoorva Ravichandran, Emily Dworkin, Caner Saygin et al.
• E23063
  Intrathecal chemotherapy and central nervous system relapse in acute lymphoblastic leukemia.

  Hannah Johnston, Yasmeen Murtaza, Wendy Stock, Austin Wesevich
• 10049
  Early-onset chronic and metabolic morbidity among survivors of childhood acute lymphoblastic leukemia: Evidence from Middle Eastern real-world data.

  Samah Hayek, Maisam Mitana, Eiron Schwartz, Shlomit Barzilai-Birenboim
• E18510
  Septicemia in acute lymphoblastic leukemia: Disparities in incidence, resource utilization, and mortality between pediatric and adult populations.

  Rigved Virendra Jeurkar, Aishwarya Ramesh, Kamleshun Ramphul, Saisree Reddy Adla Jala et al.
• E18526
  Influence of cannabis use on relapse and remission rates in patients with acute lymphoblastic leukemia (ALL).

  Eloho Olojakpoke, Deevyashali Parekh, Chidera Onwuzo, Ansy Patel et al.
• E18620
  Global burden of disease analysis of acute lymphoblastic leukemia in children in Africa: Incidence, prevalence, and DALYs (1990–2023).

  Ahmed Al Mubaid, Sibgha Fawad Memon, Zauha Fawad Memon, Sarim Hassan Shahab et al.
• 12098
  Parent willingness to enroll children with acute lymphoblastic leukemia in escalation and de-escalation clinical trials.

  Kellee Nicole Parker, Sarah Weeks Alexander, Lisa M. Jacola, Kimberly Buff et al.
• E18512
  Inotuzumab ozogamicin versus blinatumomab in pediatric relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.

  Neel Ketankumar Parikh, Bharat Parmar, Anagha Shree, Dosbai Saparov et al.
• E23441
  Bridging the access gap: First-line blinatumumab for KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) in a public health system.

  Sidnei Epelman, Thamires M.J. Mutran, Renato de Paula Guedes de Oliveira, Nevicolino Pereira De Carvalho Filho et al.
• 6551
  Comparative effectiveness and toxicity of CAR-T therapy versus blinatumomab in adult B-cell acute lymphoblastic leukemia: A real-world propensity-matched analysis.

  Colton Davis, Adithya Nagendran, Anushree Venkatesh Murthy, Logesh Durairaj et al.
• E18507
  Real-world experience with inotuzumab ozogamicin in high-risk and R/R B-cell acute lymphoblastic leukemia.

  Anshul Jain, Prashant Mehta, Jagsahib Kaur, Vidit Kapoor et al.
• 6546
  Induction failure (IF) as a prognostic marker in adult acute lymphoblastic leukemia (ALL).

  Yosef Joseph Rene Amel Riazat Kesh, Sarra Yekta, Justin Kaner, Pinkal M. Desai et al.
• E14518
  Allogeneic CD19-targeted CAR-T therapy (BRL-301) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

  YongXian Hu, Qian Susie Tan, Mingming Zhang, Guoqing Wei et al.
• 1600
  Expanding access to tyrosine kinase inhibitors for treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia in low- and middle-income countries.

  Lauren Herzog, Colin Forsyth, Alicia Annamalay, Anshika Tandon et al.
• E18513
  Kidney function trajectories in pediatric acute lymphoblastic leukemia.

  Wendy C. Bravo, Qian Liu, Tamara P. Miller, Jarcy Zee et al.
• E18577
  Allogeneic hematopoietic cell transplantation following chimeric antigen receptor T-cell (CAR-T) therapy in B-cell acute lymphoblastic leukemia (B-ALL): A systematic review and meta-analysis.

  Saad Abdul Kareem, Muhammad Talha Maqsood, Ushna Khan, Muhammad Kashif Amin et al.
• E18503
  Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: Meta-analysis of efficacy and safety outcomes.

  Mohammad Moayad Ahmad Alghaniem, Ahmad Shawabkeh, Abdulrahman Sa’d, Abdallah Al-Ramadi et al.
• E18522
  Tyrosine kinase inhibitors in Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL): A systematic review and meta-analysis.

  Bilal Ahmad, Anupama Ariyasi, Muhammad Omar Larik, Rania Rehan Khan et al.
• 6526
  ASCERTAIN: Real-world asciminib (ASC) effectiveness in patients (pts) with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

  Marlise R. Luskin, Gaurav Sutrave, Mathilde Chanut, Yok-Lam Kwong et al.
• 6529
  Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia.

  Daniel J. DeAngelo, Jae Hong Park, Vinod A. Pullarkat, Jonathan Allen Webster et al.
• 6513
  Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph + BCP-ALL).

  Elias Jabbour, Maria R. Baer, Anthony Hunter, Dennis Dong Hwan Kim et al.
• 6517
  The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).

  Jae Hong Park, Karamjeet S. Sandhu, Claire Roddie, Bijal D. Shah et al.
• 6516
  The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.

  Maria Hachem, Hannah Goulart, Nitin Jain, Lewis Fady Nasr et al.
• E19114
  Evaluation of the cytostatic properties of berberine derivatives on a cell culture of acute T-cell lymphoblastic leukemia (Jurkat).

  Nadezhda V. Gnennaya, Tatiana V. Chembarova, Svetlana Yu Filippova, Irina V. Mezhevova et al.
• 6514
  Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.

  Lewis Fady Nasr, Hannah Goulart, Nicholas James Short, Nitin Jain et al.
• 6535
  Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).

  Noam Edward Kopmar, Jonathan R. Fromm, Noah Pinke, Ted Gooley et al.
• 10000
  Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC).

  Shannon L. Maude, Susana Rives, Joerg Krueger, Kara L. Davis et al.